Development and comprehensive evaluation of a national DBCG consensus-based auto-segmentation model for lymph node levels in breast cancer radiotherapy.

Breast cancer Deep learning-based auto-segmentation National Quantitative and qualitative evaluation Radiotherapy Target delineation

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
05 Oct 2024
Historique:
received: 06 06 2024
revised: 17 09 2024
accepted: 29 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 7 10 2024
Statut: aheadofprint

Résumé

This study aimed at training and validating a multi-institutional deep learning (DL) auto segmentation model for nodal clinical target volume (CTVn) in high-risk breast cancer (BC) patients with both training and validation dataset created with multi-institutional participation, with the overall aim of national clinical implementation in Denmark. A gold standard (GS) dataset and a high-quality training dataset were created by 21 BC delineation experts from all radiotherapy centres in Denmark. The delineations were created according to ESTRO consensus delineation guidelines. Four models were trained: One per laterality and extension of CTVn internal mammary nodes. The DL models were tested quantitatively in their own test-set and in relation to interobserver variation (IOV) in the GS dataset with geometrical metrics, such as the Dice Similarity Coefficient (DSC). A blinded qualitative evaluation was conducted with a national board, presented to both DL and manual delineations. A median DSC > 0.7 was found for all, except the CTVn interpectoral node in one of the models. In the qualitative evaluation 'no corrections needed' were acquired for 297 (36 %) in the DL structures and 286 (34 %) for manual delineations. A higher rate of 'major corrections' and 'easier to start from scratch' was found in the manual delineations. The models performed within the IOV of an expert group, with two exceptions. DL models were developed on a national consensus cohort and performed on par with the IOV between BC experts and had a comparable or higher clinical acceptance than expert manual delineations.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
This study aimed at training and validating a multi-institutional deep learning (DL) auto segmentation model for nodal clinical target volume (CTVn) in high-risk breast cancer (BC) patients with both training and validation dataset created with multi-institutional participation, with the overall aim of national clinical implementation in Denmark.
MATERIALS AND METHODS METHODS
A gold standard (GS) dataset and a high-quality training dataset were created by 21 BC delineation experts from all radiotherapy centres in Denmark. The delineations were created according to ESTRO consensus delineation guidelines. Four models were trained: One per laterality and extension of CTVn internal mammary nodes. The DL models were tested quantitatively in their own test-set and in relation to interobserver variation (IOV) in the GS dataset with geometrical metrics, such as the Dice Similarity Coefficient (DSC). A blinded qualitative evaluation was conducted with a national board, presented to both DL and manual delineations.
RESULTS RESULTS
A median DSC > 0.7 was found for all, except the CTVn interpectoral node in one of the models. In the qualitative evaluation 'no corrections needed' were acquired for 297 (36 %) in the DL structures and 286 (34 %) for manual delineations. A higher rate of 'major corrections' and 'easier to start from scratch' was found in the manual delineations. The models performed within the IOV of an expert group, with two exceptions.
CONCLUSION CONCLUSIONS
DL models were developed on a national consensus cohort and performed on par with the IOV between BC experts and had a comparable or higher clinical acceptance than expert manual delineations.

Identifiants

pubmed: 39374675
pii: S0167-8140(24)03545-X
doi: 10.1016/j.radonc.2024.110567
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110567

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Emma Skarsø Buhl (E)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark. Electronic address: emskar@rm.dk.

Ebbe Laugaard Lorenzen (E)

Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Lasse Refsgaard (L)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.

Anders Winther Mølby Nielsen (A)

Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Deparment of Experimental Clinical Oncology, Aarhus University Hospital, Denmark.

Annette Torbøl Lund Brixen (A)

Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark.

Else Maae (E)

Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark.

Hanne Spangsberg Holm (H)

Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark.

Joachim Schøler (J)

Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark.

Linh My Hoang Thai (L)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.

Louise Wichmann Matthiessen (L)

Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark.

Maja Vestmø Maraldo (M)

Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.

Mathias Maximiliano Nielsen (M)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.

Marianne Besserman Johansen (M)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Marie Louise Milo (M)

Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.

Marie Benzon Mogensen (M)

Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Denmark.

Mette Holck Nielsen (M)

Department of Oncology, Odense University Hospital, Odense, Denmark.

Mette Møller (M)

Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.

Maja Sand (M)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Peter Schultz (P)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Sami Aziz-Jowad Al-Rawi (S)

Dmepartment of Clinical Oncology and Palliative Care Zealand University Hospital, Næstved, Denmark.

Saskia Esser-Naumann (S)

Dmepartment of Clinical Oncology and Palliative Care Zealand University Hospital, Næstved, Denmark.

Sophie Yammeni (S)

Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.

Stine Elleberg Petersen (S)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.

Birgitte Vrou Offersen (B)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Deparment of Experimental Clinical Oncology, Aarhus University Hospital, Denmark; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Stine Sofia Korreman (S)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Deparment of Experimental Clinical Oncology, Aarhus University Hospital, Denmark.

Classifications MeSH